p. falciparum w2

Antileishmanial agent-2 is a 3-Br-isoxazoline-Based Inhibitors against Plasmodium falciparum (D10 and W2 strains) and Leishmania spp. (L. infantum and L. tropica) Promastigotes with IC50s of 0.035, 0.058, 3.5 and 7.5 μM.

SARS-CoV-IN-1 is an effective SARS-CoV replication inhibitor with an EC50 of 4.9 μM in Vero cells.

SARS-CoV-IN-2 is an effective inhibitor of SARS-CoV replication.

SARS-CoV-IN-3 is an effective inhibitor of SARS-CoV replication.

Arterolane is an antimalarial compound. For against P. falciparum Ro73 and W2, the IC50s are both 1.1 nM.

Keenamide A, a cytotoxic cyclic hexapeptide, exhibits significant activity towards the P-388, A-549, MEL-20, and HT-29 tumor cell lines, but was inactive against the D6 and W2 Plasmodium falciparum malarial clones.

AN3661, a potent antimalarial lead compound, targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue subunit 3 (PfCPSF3) and inhibits Plasmodium falciparum laboratory-adapted strains, Ugandan field isolates, and murine P. berghei and P. falciparum infections[1].

Purfalcamine is an orally active, selective Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) inhibitor with an IC50 of 17 nM and an EC50 of 230 nM, exhibiting antimalarial activity by inducing developmental arrest of malaria parasites at the schizont stage[1][2].

Compound 24 (Compound 7), an in vitro antimalarial agent, demonstrates inhibitory activity against the Plasmodium falciparum W2 strain with an IC50 of 0.81 μM and exhibits a cytotoxicity threshold (CC50) exceeding 200 μM in HepG2 cells [1].